Cookies on Venari Partners

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we'll assume that you are happy to recieve all cookies on the Venari Partners website. However, if you would like to, you can change your cookie settings at any time.

Life Sciences

Why the US Biosimilars Market Will be slow to take off

At first glance, it appears that the US market for biosimilars is ready for takeoff In March 2015, the US Food and Drug Administration approved Zarxio from Sandoz, a biosimilar version of Amgen’s blockbuster Neupogen. Four additional biosimilar applications have been filed for FDA review.

Read More

Get More from Medtech Innovation - Pick Your Battles

For medical technology companies, innovation is a matter of priorities. At least it should be. Today, however, when its importance is greater than ever, medtech innovation productivity is in decline.  This is not a regulatory issue. The rate of regulatory approval—in terms of 510(k) and other premarket clearances—has been relatively constant since 2011. R&D budgets have been growing by 5% per year. The problem is the declining productivity of medtech companies, which is compounded by the higher burden of proof of efficacy today’s health care systems require. Large multihospital health systems have unprecedented purchasing power; they are putting more price pressure on medtech suppliers and demanding more clinical, operational, and financial benefits of medtech products.

Read More

Fixing the Medtech Commercial Model -Fixing the Medtech Commercial Model

Read More

Medtech Key Account Management in the Age of Consolidation

Read More